Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia

World Journal of Biological Psychiatry

Volumn 12, Issue 2, 2011, Pages 143-148

  Lai, I Ching ^a,b   Chen, Mao Liang ^a   Wang, Ying Chieh ^b,c   Chen, Jen Yeu ^c   Liao, Ding Lieh ^d   Bai, Ya Mei ^e   Lin, Chao Cheng ^f   Chen, Tzu Ting ^c   Liou, Ying Jay ^e,g  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

^d Pali Psychiatric Hospital   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Melatonin receptor; MTNR1A; MTNR1B; Schizophrenia; Tardive dyskinesia

Indexed keywords

MELATONIN RECEPTOR; MELATONIN RECEPTOR 1A; MELATONIN RECEPTOR 1B; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; DYSKINESIA; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, MELATONIN; SCHIZOPHRENIA;

EID: 79960081818     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.496870     Document Type: Article

References (30)

1. Abilio VC, Vera JA Jr, Ferreira LS, Duarte CR, Carvalho RC, Grassl C, et al. 2002. Effects of melatonin on orofacial movements in rats. Psychopharmacology 161:340-347. (Pubitemid 34595784)
2. Cadet JL, Kahler LA. 1994. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 18:457-467.
3. Casey DE. 1999. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 35(Suppl):S61-66. (Pubitemid 29133026)
4. Chavez JL, Anton-Tay F, Benitez-King G. 1991. Melatonin binding to D2 receptors in rat striatum: a comparative study with calmodulin antagonists. Proc West Pharmacol Soc 34:413-416.
5. Correll CU, Leucht S, Kane JM. 2004. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: asystematic review of 1-year studies. Am J Psychiatry 161: 414-425. (Pubitemid 38326094)
6. Dupont W, Plummer W. 1997. PS power and sample size program available for free on the internet. Control Clin Trials 18:274.
7. Elkashef AM, Wyatt RJ. 1999. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull 25:731-740. (Pubitemid 30013555)
8. Escames G, Acuna Castroviejo D, Vives F. 1996. Melatonindopamine interaction in the striatal projection area of sensorimotor cortex in the rat. Neuroreport 7:597-600. (Pubitemid 26105048)
9. Hamdi A. 1998. Melatonin administration increases the affi nity of D2 dopamine receptors in the rat striatum. Life Sci 63: 2115-2120. (Pubitemid 28527112)
10. Hyde TM, Egan MF, Brown RJ, Weinberger DR, Kleinman JE. 1995. Diurnal variation in tardive dyskinesia. Psychiatry Res 56:53-57.
11. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. 2006. Randomized controlled trial of the effect on Quality of Life of second-vs fi rst-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079-1087. (Pubitemid 44498387)
12. Kang SG, Choi JE, An H, Park YM, Lee HJ, Han C, et al. 2008. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 32:1844-1847.
13. Klawans HL Jr. 1973. The pharmacology of tardive dyskinesias. Am J Psychiatry 130:82-86.
14. Lee HJ, Kang SG, Choi JE, Park YM, Lim SW, Rhee MK, et al. 2009. No evidence for association between tyrosine hydroxylase gene Val81Met polymorphism and susceptibility to tardive dyskinesia in schizophrenia. Psychiatry Invest 6:108-111.
15. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353:1209-1223. (Pubitemid 41345943)
16. Naidu PS, Singh A, Kaur P, Sandhir R, Kulkarni SK. 2003. Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia. Pharmacol Biochem Behav 74:641-648. (Pubitemid 36126542)
17. National Institute of Mental Health. 1976. Abnormal involuntary movement scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual. Washington, DC: US Department of Health, Education, and Welfare. p. 534-537.
18. Reiter RJ. 1998. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 56:359-384. (Pubitemid 28389724)
19. Reiter RJ, Tan DX, Cabrera J, D'Arpa D, Sainz RM, Mayo JC, et al. 1999. The oxidant/antioxidant network: role of melatonin. Biol Signals Recept 8:56-63. (Pubitemid 29132383)
20. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. 1995. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci USA 92:8734-8738.
21. Reppert SM, Weaver DR, Ebisawa T. 1994. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 13: 1177-1185. (Pubitemid 24372135)
22. Sandyk R, Fisher H. 1988. The protective function of the pineal gland in tardive dyskinesia. Int J Neurosci 43:215-218.
23. Sandyk R, Fisher H. 1989. Melatonin mediates the antidyskinetic effects of naloxone in tardive dyskinesia. J Clin Psychopharmacol 9:147-148.
24. Schooler NR, Kane JM. 1982. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487. (Pubitemid 12152819)
25. Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, et al. 2001. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 58:1049-1052. (Pubitemid 33051830)
26. Suh Y, Vijg J. 2005. SNP discovery in associating genetic variation with human disease phenotypes. Mutat Res 573:41-53.
27. Sullivan PF. 2007. Spurious genetic associations. Biol Psychiatry 61:1121-1126. (Pubitemid 46669468)
28. Uz T, Akhisaroglu M, Ahmed R, Manev H. 2003. The pineal gland is critical for circadian Period1 expression in the striatum and for circadian cocaine sensitization in mice. Neuropsychopharmacology 28:2117-2123. (Pubitemid 37468179)
29. Zhao JH. 2004. 2LD, GENECOUNTING and HAP: Computer programs for linkage disequilibrium analysis. Bioinformatics 20:1325-1326. (Pubitemid 38807588)
30. Zisapel N, Egozi Y, Laudon M. 1982. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res 246:161-163. (Pubitemid 12048856)